The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 16, 2013

Filed:

Sep. 19, 2011
Applicants:

Nicole M. Alessandri Haber, Rye, NY (US);

Lynn Macdonald, White Plains, NY (US);

Michael L. Lacroix-fralish, Sleepy Hollow, NY (US);

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Inventors:

Nicole M. Alessandri Haber, Rye, NY (US);

Lynn Macdonald, White Plains, NY (US);

Michael L. LaCroix-Fralish, Sleepy Hollow, NY (US);

Andrew J. Murphy, Croton-on-Hudson, NY (US);

Assignee:

Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US);

Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
C07K 14/705 (2006.01); C07K 19/00 (2006.01); C12N 15/62 (2006.01); G01N 33/567 (2006.01);
U.S. Cl.
CPC ...
Abstract

Methods and compositions for using genetically modified non-human animals are provided, wherein the genetic modification comprises a humanization of the one or more extracellular pore loops of a Na1.7 channel protein or a complete humanization of an endogenous Na1.7 gene. Methods for using isolated DRG cultures from genetically modified non-human animals are also provided, wherein the isolated DRG express a human or chimeric Na1.7 protein on the surface, in particular measuring primary nociceptive activation through the release of calcitonin gene-related peptide (CGRP) in isolated DRG in vitro, and wherein the isolated DRG cultures are capable of generating action potentials and communicating through an excitable signal via the expressed human or chimeric Na1.7 protein the cell surface. In vivo and in vitro methods for characterizing Na1.7-specific antagonists and evaluation of corresponding therapeutic potential for Na1.7-mediated disease are also provided.


Find Patent Forward Citations

Loading…